Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
New England Journal of Medicine, 2016 · paper · Clinical trials
An open-label trial of 305 patients with previously untreated advanced lung cancer with high PD-L1 expression, comparing pembrolizumab with platinum chemotherapy. Pembrolizumab gave longer progression-free and overall survival and fewer adverse events.
0 findings
None that passed a second check.
1 minor (typos and the like; most checked by the judge only)
Wording Methods describe the ECOG score as "score of 0 or 1 (on a 5-point scale, with 0 indicating no symptoms", while the Table 1 footnote and Figure 1 legend say "performance-status scores range from 0 to 5", which is six levels.
- p. 2 Methods, Patients
score of 0 or 1 (on a 5-point scale, with 0 indi-
- p. 5 Table 1, footnote †
performance-status scores range from 0 to 5
- p. 7 Figure 1 legend
(ECOG) performance-status scores range from 0 to 5,
Judge's note: Viewed all three crops. Page 2 prints "on a 5-point scale"; the Table 1 footnote (page 5) and the Figure 1 legend (page 7) both print "scores range from 0 to 5". A 0-to-5 range has six score values, so the two descriptions differ literally. This may be house-style wording (maximum score 5, or grade 5 = death left out), and no data are affected, so it is a minor consistency point where either form could be intended.
Second check: another model agreed